drugset
drugset / Trial / NCT07120607

Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia

NCT07120607 ↗

Phase 1 Not yet recruiting 9 enrolled Anhui Provincial Hospital
NaSingle-groupOpen-labelTreatment

Summary

CD7 is highly expressed in T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma. Approximately 10-30% of cute myeloid leukemia(AML) patients exhibit CD7 expression, particularly in early myeloid progenitor cell-derived AML (e.g., M0/M1 subtypes), mixed-phenotype acute leukemia (MPAL), and AML with high-risk genetic abnormalities (such as TP53 mutations or complex karyotypes). CD7-positive AML patients typically have poor prognosis, poor response to standard chemotherapy, and shorter overall survival (OS). Targeted CD7 cell therapies may represent a promising direction for the treatment of these diseases.

Timeline

Start
2025-08-18
Primary completion
2026-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject CD7 CAR-γδT cell Cell therapy 1e+08 cells Intravenous
Subject CD7 CAR-γδT cell Cell therapy 3e+08 cells/kg Intravenous
Subject CD7 CAR-γδT cell Cell therapy 6e+08 cells Intravenous
Background Cyclophosphamide Other / unclassified 500 mg/m2 Intravenous
Background Cyclophosphamide Other / unclassified 1000 mg/m2 Intravenous
Background Fludarabine Small molecule 30 mg/m2 Intravenous
Background Fludarabine Small molecule 50 mg/m2 Intravenous

Indications

leukemia